The review of the Russian biotech drugs market
DOI:
https://doi.org/10.32687/1561-5936-2024-28-4-329-336Keywords:
biotech drugs, recombinant DNA technology, biosimilars, original drugs, monoclonal antibodies, the Russian pharmaceutical market, the Russian pharmaceutical industryAbstract
The biopharmaceutical industry is a major source of innovation and a driver of development of both the global pharmaceutical market and the different national markets, including the Russian one. The development of the Russian market of biotech drugs was facilitated by the expansion of state drug supply programs and the formation of the Russian pharmaceutical industry. The aim of the study was to assess the nomenclature, volumes and values, dynamics and structure of the Russian BD market in 2013–2023. BDs were identified as medicinal products obtained using recombinant DNA technology. Materials and methods. The study was based on the state registration, patent and scientific information, as well as sales data of DSM Group. Market segmentation was carried out considering the allocated groups of BDs, as well as ATC classification system. Results and discussion. In 2023 in Russia the sales value of BD related to 168 INNs amounted to RUB 288.4 billion in wholesale prices. In the sales structure, the main BD groups were mAbs and hormones. The leading therapeutic classes were antineoplastic agents and immunosuppressants, while orphan drugs accounted for 27.3% of the sales. Since 2013, the compound annual growth rates of BD sales in Russia have exceeded the global figures. BD's share in the Russian pharmaceutical market was significantly smaller than in the global market. Market share of biosimilars mostly represented by domestic products was high. The share of Russian-made drugs mainly provided by a limited list of companies increased to 30.8% by 2023 due to the development of biosimilars and original drugs. Conclusion. The BD segment has been remained as the most actively developing part of the Russian pharmaceutical market, where are concentrated the activities of the leading Russian companies aimed at the development of biosimilars and original drugs.References
Sanchez-Garcia L., Martín L., Mangues R. et al. Recombinant pharmaceuticals from microbial cells: a 2015 update. Microb. Cell Fact. 2016;15:33. DOI: 10.1186/s12934-016-0437-3
López-Siguero J. P., Palla Garcia M., Martínez Busto E. et al. Ten years experience with the first approved biosimilar recombinant human growth hormone drug in normal clinical practice. Anales de pediatria. 2018;88(4):209–215. DOI: 10.1016/j.anpe-di.2017.03.007
Gabibov A. G., Ponomarenko N. A., Vorobyev I. I. et al. Prospects for designing Russian gene engineering agents for medicine. Rastan is the first Russian recombinant human growth hormone. Problems of Endocrinology. 2007;53(2):19–24. DOI: 10.14341/probl200753219-24
Trofimova E. O., Denisova M. N. Results of the development of the public sector of the Russian pharmaceutical market in 2019—2021. Remedium. 2022;26(4):318–324. DOI: 10.32687/1561-5936-2022-26-4-318-324
Khalimova A. A. Definition and classification of biotechnological drugs for the purposes of economic analysis. In: Challenges of globalization and the development of digital society in the new reality. Proceedings of the IX International Scientific and Practical Conference (Pyatigorsk, July 10, 2023). Makhachkala; 2023:22–32. DOI: 10.34755/IROK.2023.96.20.093 (In Russ.)
Khalimova A. A., Orlov A. S., Taube A. A. Analysis of biopharmaceutical manufacturing localization in Russia considering the country of origin of active pharmaceutical ingredients. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2024;14(1):53–61. DOI: 10.30895/1991-2919-2024-14-1-53-61
Downloads
Published
Issue
Section
License
Authors retain copyright and grant the journal right of the first publication. The article simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
By submitting the article and accompanying files (hereinafter – the “Work”) the author (all the authors of the work, if it is created in co-authorship) agrees that he provides OAO Izdatelstvo Meditsina exclusive and perpetual right to use the work free of charge (exclusive, perpetual and royalty-free license) on the territory of Russia and foreign countries in the following ranges and volume:
- the publication of works on paper and / or electronic format, producing reprints of works, placing it on the Internet, both in the open and paid access, sending works metadata or full text indexing to various databases and repositories;
- reproduction of the work, i.e. the production of one or more copies of a work or part thereof in any material form, including in the form of audio or video recording. Recording on electronic media, including recording in computer memory, is also considered as a reproduction;
- distribution of works through sale or other alienation of its original or copies;
- public display of the work, that is, any demonstration of the original or copy of a work, either directly or on the screen using film, slide, television pictures or other technical means, as well as a demonstration of individual frames of an audiovisual work without concern for their order, either directly or with the help of technical means in a place open for free visits, or in a place where a significant number of individuals do not belong to the normal family, regardless of the perceived in the place of its display or elsewhere at the same time demonstrating product;
- import-export of the work or its parts for any lawful purpose (paid and gratis);
- translation or other processing of the works;
- bringing the work to the public so that anyone can access the work from any place and at any time of their choice;
- accommodation of works or parts thereof in a variety of collections of similar works;
- granting of rights in full or in part to third (physical and legal) persons at both the paid and free of charge.
Author’s items are not provided. The title is available by subscription.
